SLC5A2 and chronic kidney disease: This difference may be partly due to higher underlying chronic inflammation levels, differences in metabolic status, and underlying medication use (e.g., SGLT2 inhibitors, statins, etc.)in patients with CKD, which may somewhat ‘mask’ the effects of moderate SII, with significant increases in risk only observed in the higher SII level.